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Abstract
Purpose Sigma receptors are implicated in memory and
cognitive functions, drug addiction, depression and schizo-
phrenia. In addition, sigma receptors are strongly overex-
pressed in many tumours. Although the natural ligands are
still unknown, steroid hormones are potential candidates.
Here, we examined changes in binding of the sigma-1
agonist
11C-SA4503 in C6 glioma cells and in living rats
after modification of endogenous steroid levels.
Methods
11C-SA4503 binding was assessed in C6 mono-
layers by gamma counting and in anaesthetized rats by
microPET scanning. C6 cells were either repeatedly washed
and incubated in steroid-free medium or exposed to five
kinds of exogenous steroids (1 h or 5 min before tracer
addition, respectively). Tumour-bearing male rats were
repeatedly treated with pentobarbital (a condition known
to result in reduction of endogenous steroid levels) or
injected with progesterone.
Results Binding of
11C-SA4503 to C6 cells was increased
(~50%) upon removal and decreased (~60%) upon addition
of steroid hormones (rank order of potency: progesterone >
allopregnanolone = testosterone = androstanolone > dehy-
droepiandrosterone-3-sulphate, IC50 progesterone 33 nM).
Intraperitoneally administered progesterone reduced tumour
uptake and tumour-to-muscle contrast (36%). Repeated
treatment of animals with pentobarbital increased the PET
standardized uptake value of
11C-SA4503 in tumour (16%)
and brain (27%), whereas the kinetics of blood pool
radioactivity was unaffected.
Conclusions The binding of
11C-SA4503 is sensitive to
steroid competition. Since not only increases but also
decreases of steroid levels affect ligand binding, a consid-
erable fraction of the sigma-1 receptor population in
cultured tumour cells or tumour-bearing animals is normal-
ly occupied by endogenous steroids.
Keywords Steroidhormones.Positron emission
tomography(PET).Glioma.Sigmareceptor ligand.
11C-SA4503
Introduction
The use of positron emission tomography (PET) for
imaging of cancer has a successful history spanning more
than three decades. Suitable radiopharmaceuticals have
been designed to track molecular events in the body, to
monitor the time course of disease and to assess treatment
outcome. Although
18F-FDG and other metabolic PET
tracers (
18F-FLT,
11C-methionine,
11C-choline, etc.) are
widely available for the diagnosis of cancer and monitoring
of treatment response, these tracers are not tumour specific
and/or have only moderate cellular uptake [1, 2]. For this
reason, there is much interest in the development and
validation of novel radiopharmaceuticals with greater
tumour selectivity. Attractive candidates are sigma ligands
since sigma receptors are strongly overexpressed in rapidly
proliferating cells [3–6].
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sequence (87–92% identity and 90–93% homology for
sigma-1 receptor) [7]. They are found in kidney, liver,
immune, endocrine and reproductive organs [8]. Further-
more, sigma receptors are widely distributed in the brain
and are implied in memory function, cognition, drug
addiction, depression and schizophrenia [9]. Importantly,
sigma receptors were demonstrated to play a role in tumour
cell proliferation and cancer cell death. These binding sites
are therefore important targets in the development of novel
anti-cancer drugs [10]. Although the endogenous ligands
for sigma receptors have not yet been identified, steroid
hormones (in particular progesterone) are potential candi-
dates [11, 12].
Recent work has demonstrated regulation of sigma-1
receptor availability by endogenous steroids. Such steroids
modulate the efficacy of a sigma-1 receptor agonist in stress
and depression [12]. Binding of neurosteroids to sigma
receptors affects the release of substance P from nociceptor
endings in mice [13] and the release of glutamate and
norepinephrine in rat prelimbic cortex and hippocampus
[14, 15]. Furthermore, such binding reduces subjective
craving in cocaine addiction [16]. Based on their effects
on substance P and norepinephrine release, progesterone
was proposed to be a sigma antagonist, whereas de-
hydroepiandrosterone-3-sulphate (DHEA-S) and pregneno-
lone sulphate were considered as sigma agonists [13, 15].
Multiple sequence analyses revealed the presence of two
steroid-like binding domains (SBDLI and SBDLII) in the
guinea pig sigma-1 receptor (amino acids 91–109 and 176–
194, respectively) [17, 18]. Recently, it was shown that
administration of steroids reduces in vivo binding of the
sigma-1 receptor ligand
18F-FPS in rodent brain [19].
Although an interaction between cerebral sigma recep-
tors and steroids has been established, our knowledge about
competition between sigma ligands and endogenous ste-
roids in cancer cells is still rudimentary. Moreover, it
remains necessary to examine how steroid hormones affect
the binding of radiopharmaceuticals other than
18F-FPS,
since sigma ligands may bind to different receptor subtypes
[20] and to different binding sites within the sigma-1
receptor molecule (e.g. the agonist binding site and the
phenytoin-binding site [21]).
Here, we examine the impact of steroid competition on
binding of the sigma-1 agonist
11C-SA4503.
11C-SA4503
has been used extensively for PET studies of animal
tumours [2, 22–24] and the human brain [25–28]. For in
vitro tests of steroid competition, we used C6 rat glioma
cells, a tumour line which expresses both sigma-1 and
sigma-2 receptors [3]. As an in vivo model we used C6
glioma-bearing Wistar rats. Tumour cells were either
repeatedly washed and incubated in steroid-free medium
or exposed to five different exogenous steroids. Rats were
either repeatedly injected with pentobarbital, a treatment
known to reduce the levels of endogenous steroids [29], or
injected with progesterone. If the binding of
11C-SA4503 is
sensitive to competition by endogenous steroids, we
expected to find increased tracer binding after prolonged
anaesthesia and decreased binding after steroid addition.
Such competition, if present, could result in intrasubject
variability of the binding potential of
11C-SA4503 in
women during the menstrual cycle and also in intersubject
variability in aged subjects which may show widely
different endogenous steroid concentrations.
Materials and methods
Culture media and drugs
Dulbecco’s minimum essential medium (DMEM), fetal calf
serum (FCS) and trypsin were products of Invitrogen.
Allopregnanolone acetate (5α-pregnan-3β-ol-20-one 3β-
acetate), dehydroepiandrosterone 3-sulphate sodium salt
(DHEA-S), haloperidol, progesterone (cell culture tested,
P8783) and trypan blue (0.4% solution in phosphate-buffered
saline) were purchased from Sigma. Androstanolone (5α-
androstan-17β-ol-3-one) and testosterone were obtained
from Fluka. Matrigel
R came from Becton Dickinson.
Arachid oil was a product of Levo BV, Franeker, Holland.
Stock solutions of steroids and of haloperidol were prepared
in ethanol unless otherwise indicated. The radioligand
11C-
SA4503 was prepared by reaction of
11C-methyl iodide with
the appropriate 4-O-methyl precursor [30]. The decay-
corrected radiochemical yield was 9–11%, the specific
radioactivity >11 TBq/mmol at the moment of injection
and radiochemical purity >95%.
Cell culture
C6 rat glioma cells obtained from the American Type
Culture Collection were grown as monolayers in DMEM
(high glucose) supplemented with 7.5% FCS in a humid-
ified atmosphere of 5% CO2/95% air at 37°C. Before each
experiment, the cells were seeded in 12-well plates
(Costar). An equal number of cells were dispensed in each
well in 1.1 ml of serum-containing medium: DMEM (high
glucose) supplemented with 7.5% FCS.
Binding studies
Binding studies were performed 48 h after seeding cells in
12-well plates when confluency had reached 80–90%. In
some experiments, cells were steroid-depleted by removal
of the normal medium, repeated (3 ×) washing with
phosphate-buffered saline (PBS, 1 ml) and addition of
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before addition of the radiotracer. Various concentrations of
an unlabelled competitor (haloperidol or a steroid) were
dispensed to the culture medium in the wells. Steroids
investigated were allopregnanolone, androstanolone,
DHEA-S, progesterone and testosterone. After 2 min,
4 MBq of
11C-SA4503 in <30 µl of saline (containing
30% ethanol) were added to each well. After 45–60 min of
incubation, the medium was quickly removed and the
monolayer was washed 3 times with PBS. Cells were then
treated with 0.2 ml of trypsin. When the monolayer had
detached from the bottom of the well, 1 ml of DMEM (high
glucose) supplemented with 7.5% FCS was added to stop
the proteolytic action. Cell aggregates were resolved by
repeated (at least tenfold) pipetting of the trypsin/DMEM
mixture. Radioactivity in the cell suspension (1.2 ml) was
assessed using a gamma counter (Compugamma 1282 CS,
LKB-Wallac, Turku, Finland). A sample of the suspension
was mixed with trypan blue solution (1:1 v/v) and was used
for cell counting. Cell numbers were determined manually,
using a phase contrast microscope (Olympus, Tokyo,
Japan), a Bürker bright-line chamber (depth 0.1 mm;
0.0025 mm
2 squares) and a hand tally counter. All experi-
ments were performed as a quadruplicate study with at least
two repeats.
Animal model
The animal experiments were performed by licensed
investigators in compliance with the Law on Animal
Experiments of The Netherlands. The protocol was ap-
proved by the Committee on Animal Ethics of the
University of Groningen.
C6 glioma cells [2.5×10
6, in a 1:1 mixture of Matrigel
and DMEM (high glucose with 7.5% FCS)] were subcuta-
neously injected into the right shoulder of male Wistar rats.
The animals were maintained at a 12 h light/12 h dark
regime and were fed standard laboratory chow ad libitum.
They were scanned after 9–10 days, when tumours had
grown to above 0.5 g.
MicroPET scanning
Two rats were scanned simultaneously in each scan session,
using a Siemens/Concorde microPET camera (Focus 220).
A list mode protocol was used (60 min, brain, tumour and
upper half of both lungs in the field of view). These organs
were clearly visualized, as reported previously [24]. The
scanning was started during injection into the first rat; the
second rat was injected 30 s later. Body temperature of
anaesthetized animals in the scanner was kept at 37.5±
0.5°C, using rectal probes, individual temperature control-
lers and electronic heating (M2M Imaging).
Two microPET scans of five rats were made in order to
explore the effect of anaesthesia duration on the in vivo
binding of
11C-SA4503 (23–27 MBq administered as a
0.3 ml bolus, tail vein catheter, mass <2 nmol). For the first
scan, the tracer was injected shortly (<20 min) after the
induction of pentobarbital anaesthesia (first scan = control
condition). When this scan had been finished, the animal
was kept under anaesthesia and remained at a fixed position
in the microPET scanner.
11C-SA4503 was once more
injected after prolonged anaesthesia [four intraperitoneal
injections of a sodium pentobarbital solution in water
(60 mg/ml): first injection 1 ml/kg body weight, and then
three subsequent 0.3 ml/kg body weight at 30–40 min
intervals, total anaesthesia duration >3.5 h] in order to
acquire the second scan.
For examination of the effect of an exogenous steroid on
11C-SA4503 binding, microPET scans were made of four
pairs of rats. One rat of each pair was treated with
progesterone (three intraperitoneal injections of 10 mg each
at 1.5-h intervals, in arachid oil, progesterone-treated
group), whereas the other animal was treated with carrier
(arachid oil) only (control group). In the arachid oil- and
progesterone-treated rats, the tracer
11C-SA4503 was
injected shortly (< 20 min) after the induction of pentobar-
bital anaesthesia.
List mode data were reframed into a dynamic sequence
of 4×60 s, 3×120 s, 4×300 s and 3×600 s frames. The data
were reconstructed per time frame employing an interactive
reconstruction algorithm (OSEM2D). The final data sets
consisted of 95 slices with a slice thickness of 0.8 mm and
an in-plane image matrix of 128×128 pixels of size 1×
1m m
2. Data sets were fully corrected for random
coincidences, scatter and attenuation. A separate transmis-
sion scan was acquired for attenuation correction. This scan
was performed right after the last emission scan.
Three-dimensional regions of interest (3-D ROIs) were
manually drawn around the entire tumour, brain and
peripheral area of the right lung, avoiding hilar structures,
as described previously [24]. Time-activity curves (TACs)
and volumes (cm
3) for the ROIs were calculated, using
standard software (AsiPro VM 6.2.5.0, Siemens-Concorde,
Knoxville, TN, USA). TACs were normalized for body
weight and injected dose as indicated in the figure legends.
Biodistribution studies
After the scanning period, the anaesthetized animals were
terminated. Blood was collected, and plasma and a cell
fraction were obtained from the blood sample by short
centrifugation (5 min at 1,000 g). Several tissues (see
Table 1) were excised. The complete tumour was removed
and separated from muscle and skin. All tissue samples were
weighed. Radioactivity intissue samples was measured using
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were expressed as dimensionless standardized uptake values
(SUVs). The parameter SUV is defined as: [tissue activity
concentration (MBq/g) * body weight (g) / injected dose
(MBq)].
Results
Cell experiments
The growth medium of C6 cells (DMEM-high) contains
steroid hormones since it is supplemented with FCS (7.5%
v/v). This medium also contains the indicator phenol red
which may interact with hormone binding sites, particularly
oestrogen receptors [31]. Yet, the addition of non-
radioactive steroids to normal growth medium (50 µM of
progesterone, allopregnanolone, testosterone or androstano-
lone) resulted in measurable competition with the radio-
ligand
11C-SA4503 for binding to cellular sigma receptors
(Fig. 1). In contrast, the administration of 50 µM DHEA-S
had no statistically significant effect.
Table 1 Effect of prolonged anaesthesia and progesterone administration on biodistribution of
11C-SA4503
Tissue Control
a
(n=4)
Prolonged anaesthesia
b
(n=5)
Progesterone-treated*
(n=4)
Effect of long
anaesthesia (p)
Effect of
progesterone (p)
Cerebellum 1.66±0.18 2.41±0.33 1.69±0.30 < 0.01 NS
Cerebral cortex 1.50±0.40 2.38±0.40 1.85±0.33 0.02 NS
Rest of brain 1.51±0.38 2.12±0.41 1.69±0.37 NS NS
Adipose tissue 0.25±0.12 0.38±0.15 0.25±0.08 NS NS
Bladder 0.67±0.16 0.80±0.31 0.55±0.17 NS NS
Bone 0.27±0.08 0.42±0.09 0.34±0.11 < 0.05 NS
Bone marrow 1.56±0.36 2.15±0.23 1.17±0.20 < 0.05 NS
Heart 0.35±0.09 0.48±0.07 0.31±0.04 NS NS
Large intestine 1.82±0.36 2.62±0.39 1.87±0.39 < 0.05 NS
Small intestine 2.35±0.28 3.48±0.86 2.73±0.53 NS NS
Kidney 4.07±0.45 4.60±0.19 4.07±0.63 NS NS
Liver 7.53±0.77 5.20±0.28 7.16±1.39 0.001 NS
Lung 2.21±0.59 2.51±0.62 1.92±0.50 NS NS
Muscle 0.18±0.04 0.21±0.01 0.20±0.05 NS NS
Pancreas 3.78±1.55 5.06±1.22 5.16±1.60 NS NS
Plasma 0.09±0.03 0.10±0.02 0.09±0.01 NS NS
Blood cells 0.05±0.01 0.07±0.01 0.05±0.01 < 0.05 NS
Spleen 2.26±0.39 3.76±0.95 2.07±0.41 < 0.05 NS
Submandibular gland 2.91±0.91 2.08±0.17 2.59±0.85 NS NS
C6 tumour 0.83±0.11 1.52±0.36 0.57±0.14 < 0.05 < 0.05
Urine 0.48±0.20 0.75±0.76 0.92±0.29 NS < 0.05
SUV values of
11C, 60 min after injection of
11 C-SA4503
aData were obtained from the control and progesterone-treated rats, respectively, after the PET scan of Fig. 4
bData were obtained from the rats which had undergone the two PET scans of Fig. 3
Fig. 1 Competition of exogenous steroids (concentration 50 µM) and
haloperidol (50 µM) with
11C-SA4503 binding to C6 cells in normal
culture medium and in steroid-free medium (expressed as a percentage
of the binding to untreated cells in normal culture medium). All
treatments resulted in a statistically significant effect on tracer binding,
with exception of the DHEA-S effect in normal culture medium
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removal of growth medium, repeated washing of the
monolayer with PBS and addition of medium without
FCS and phenol red. Such steroid depletion resulted in a
significant (49±4%) increase of the specific binding of
11C-
SA4503 to intact cells (Fig. 1).
When the steroid supplementation experiment was repeat-
ed in steroid-free medium, a stronger effect of exogenous
steroids was observed than in the normal growth medium.
Even 50 µM DHEA-S caused now a significant decrease of
cellular
11C-SA4503 binding (Fig. 1). Both in normal and in
steroid-depleted medium, the observed rank order of potency
was: progesterone > androstanolone = testosterone =
allopregnanolone > DHEA-S. A dose-response plot was
made for the most potent steroid competitor, progesterone.
The IC50 value of this compound for inhibition of cellular
11C-SA4503 binding was 33 nM (Fig. 2).
Addition of the anaesthetic pentobarbital to C6 cells (up to
concentrations of 1 mM in normal medium) did not result in
any inhibition of
11C-SA4503 binding (values not shown).
Animal data
No behavioural changes were observed in the animals up to
10 days after inoculation of C6 cells. Tumours appeared
after 5 days and grew exponentially, as reported previously
[24]. Body weight of the animals at the time of PET
scanning was 326±22 g. Tumour size was then 1.3±0.7 g
(mean ± SD, range 0:.48–2.39 g). No significant tumour
necrosis was observed, as reported previously [2].
MicroPET scans
Pentobarbital anaesthesia is known to affect steroid metab-
olism. A strong (> 70%) decline of endogenous steroid
levels in the brain (progesterone, pregnenolone) occurs
upon treatment of male rats with anaesthetic amounts of
sodium pentobarbital (0.2 mmol/kg i.p., [29]). Plasma
progesterone in female rats is also decreased after pento-
barbital administration [32]. Thus, competition of endoge-
nous steroids with
11C-SA4503 binding in target organs
was expected to be reduced after repeated treatment of
Wistar rats with pentobarbital. A significant increase of
tracer SUV in target organs (brain 27%, C6 tumour 16%)
was indeed observed after prolonged anaesthesia (Fig. 3).
However, anaesthesia duration did not significantly affect
the kinetics of radioactivity in a blood pool from the right
lung (Fig. 3).
Pretreatment of animals with a high dose of progesterone
resulted in a significant decrease of ligand SUV in the C6
tumour (36 %), but did not significantly affect tracer
kinetics in the brain or blood pool (Fig. 4).
MicroPET images of a single rat acquired after short and
prolonged anaesthesia are shown in Fig. 5. Images of
solvent (arachid oil)- and progesterone-pretreated animals
are presented in Fig. 6.
Biodistribution studies
Biodistribution experiments confirmed the outcome of the
microPET studies (Table 1). Prolonged anaesthesia with
pentobarbital resulted in a significant increase of sigma
ligand binding in C6 tumour, brain (particularly cerebellum
and cerebral cortex), bone and bone marrow, large intestine,
blood cells and spleen. Plasma levels of radioactivity were
not changed under these conditions and the amount of
radioactivity in the liver was significantly decreased.
Pretreatment of animals with progesterone caused a 31%
decrease of sigma ligand binding in the C6 tumour, but did
not significantly affect tracer uptake in any other organ or
in plasma (Table 1).
Discussion
In vitro steroid competition
Although an interaction of steroid hormones with sigma
receptors has been described in many publications, there are
few reported observations of competition between endog-
enous steroids and sigma receptor ligands in intact cancer
cells. Here, we demonstrate that altered steroid levels result
in changes of
11C-SA4503 binding to sigma receptors in the
C6 glioma cell line. Steroid depletion (removal of FCS
from the growth medium and washing of cells with steroid-
free medium) resulted in a 49% increase of
11C-SA4503
binding. Apparently, high steroid levels in the normal
growth medium result in reduced tracer binding and can
Fig. 2 Dose-response plot of progesterone competition with
11C-
SA4503 binding to C6 cells in steroid-free medium. Specific binding
was defined as total binding minus the residual binding observed in
the presence of an excess of haloperidol (50 µM)
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affinity to sigma receptor proteins. Enhanced competition
of DHEA-S and other steroids with
11C-SA4503 binding
was observed when cells were washed and incubated in
steroid-free medium, 1 h before tracer addition.
Testosterone (50 µM), an androgen secreted by the testis,
caused a 40% reduction of radioligand binding to C6 cells
in steroid-free medium. Androstanolone (dihydrotestoster-
one), a metabolite of testosterone which mediates many of
the biological actions of testosterone, had a similar effect as
the parent compound. Dehydroepiandrosterone sulphate, a
Fig. 4 Time-activity curves of
11C-SA4503-derived radioactivity in
tumour, brain and blood pool. Solid line: animals scanned at baseline
(treated with arachid oil only, control group, n=4); dotted line: other
animals scanned after repeated injections of progesterone in arachid
oil (progesterone-treated group, n=4). The PET data were normalized
to a body weight of 330 g and an injected radioactivity dose of
20 MBq, as described previously [24]. The effect of progesterone
addition on tumour uptake (but not brain or blood pool uptake) was
statistically significant
Fig. 3 Time-activity curves of
11C-SA4503-derived radioactivity in
tumour, brain and blood pool. Solid line: animals scanned after short
pentobarbital anaesthesia (< 20 min, control condition, n=5); dotted
line: same animals scanned after protracted pentobarbital anaesthesia
(>3.5 h, n=5). The PET data were normalized to a body weight of
330 g and an injected radioactivity dose of 20 MBq, as described
previously [24]. The effect of protracted anaesthesia on brain uptake
(after >10 min) and tumour uptake (after >20 min) was statistically
significant, in contrast to the effect on radioactivity in the blood pool
1172 Eur J Nucl Med Mol Imaging (2009) 36:1167–1175steroid sigma agonist with antidepressant actions and an
allosteric modulator of γ-aminobutyric acid (GABA)A
receptors, was the weakest competitor for
11C-SA4503
binding. The most potent steroid inhibitor proved to be
progesterone (secreted by the corpus luteum in females)
which reduced cellular
11C-SA4503 binding by 60%.
Allopregnanolone, an important metabolite of progesterone,
was less potent than its parent compound, but still caused a
33% reduction of radioligand binding. Non-specific binding
(defined as binding of the radioligand to C6 cells in the
presence of an excess of haloperidol) was about 25% in
normal growth medium and 18% in steroid-free medium
(Fig. 1).
The results of our experiments in cancer are in
accordance with previous studies which have employed
different radioligands and have focused on healthy tissue.
Progesterone and testosterone were shown to compete with
the binding of
3H-SKF-10,047 and
3H-haloperidol to sigma
receptors in homogenates from guinea pig brain and spleen
[33]. These steroids were also potent inhibitors of the
binding of
3H-haloperidol to sigma-1 receptors in human
placenta [11], and they reduced binding of the sigma-1
ligand
18F-FPS to isolated membrane fragments and to the
brain of intact rats [19]. Progesterone acted like a sigma-1
antagonist in the rat hippocampus, mimicking the effects of
haloperidol on
3H-norepinephrine release [15]. Progester-
one but not dehydroepiandrosterone sulphate reduced the in
vivo binding of
3H-SKF-10,047 to sigma-1 receptors in the
mouse hippocampus and cortex [34].
In vivo steroid competition
Progesterone supplementation reduced tumour SUV (from
0.83±0.11 to 0.57±0.14) and the tumour-to-muscle con-
centration ratio (from 4.6 to 2.8), as indicated by our
biodistribution data (Table 1). TACs in microPET indicated
a progesterone-mediated decrease of
11C-SA4503 binding
in the C6 tumour (by 36%), but not in the brain (Fig. 4).
The reason for the absence of an effect of progesterone
supplementation on radioligand binding in the brain of
intact rats is unknown. P-glycoprotein (Pgp) function in the
blood-brain barrier hampers the entry of exogenous
progesterone into the brain [35], whereas C6 tumours do
not express Pgp (personal observations). Therefore, exog-
enous progesterone can freely enter the implanted C6
tumour, but can enter the brain only to a limited extent.
Our data suggest that not only steroid supplementation—
as reported previously for other sigma ligands—but also
removal of steroid is accompanied by changes of the in
vivo binding of
11C-SA4503. Repeated treatment of
animals with pentobarbital increased tumour SUV (from
0.83 to 1.52) and the tumour to muscle ratio (from 4.6 to
7.2, Table 1). Tracer SUV in cerebellum and cerebral cortex
was also increased (from 1.66 to 2.41 and from 1.50 to
2.38, respectively, Table 1). TACs in the microPET experi-
ments indicated increased
11C-SA4503 binding both in the
C6 tumour (by 16%) and in the brain (by 27%, Fig. 3).
Prolonged pentobarbital anaesthesia and progesterone sup-
plementation were not accompanied by any significant
change of the blood activity curves of
11C-SA4503 (Figs. 2
and 3). Altered tracer binding to sigma-1 receptors in
tumour and brain appears therefore to be related to changes
within target tissue rather than to altered tracer delivery to
the target organs. Since pentobarbital has multiple effects
on cerebral biochemistry, our data do not prove that the
effect of prolonged anaesthesia is due to an interference of
pentobarbital with steroid metabolism. However, the infor-
mation from our microPET and biodistribution studies is
Fig. 5 MicroPET images of a single animal scanned with
11C-
SA4503 after short (<20 min, upper row) and protracted (>3.5 h,
lower row) pentobarbital anaesthesia. Images are summed data from 1
to 60 min after injection. The positions of tumour and brain are
indicated by capitals T and B
Fig. 6 MicroPET images of two different rats scanned with
11C-
SA4503 after pretreatment with solvent (arachid oil, upper row)o r
progesterone (lower row). Images are summed data from 1 to 60 min
after injection. The positions of tumour and brain are indicated by
capitals T and B
Eur J Nucl Med Mol Imaging (2009) 36:1167–1175 1173consistent with the hypothesis that prolonged pentobarbital
anaesthesia results in reduced levels of endogenous steroid
hormones.
Conclusion
Steroid competition affects binding of the sigma ligand
11C-
SA4503 in tumour cells and tumour-bearing rats. Progester-
one, the most potent steroid competitor of
11C-SA4503
binding, showed an IC50 value in tumour cells of 33 nM, or
10 ng/ml (Fig. 2). Similar levels of progesterone (3–28 ng/ml)
are reached in human plasma during the luteal phase of the
menstrual cycle [36] and even higher levels occur during
hormone treatment. Moreover, steroid levels may change
during chemotherapy, both in male and female patients
[37–40]. Therefore, (patho)physiological variations of these
levels can result in variability of the binding potential of
11C-SA4503 and should be taken into account in PET studies
of patients and healthy volunteers.
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